PMS Registry
Company Name
Bayer Taiwan Co., Ltd
Protocol Number
21960
Title of Study
Copanlisib in Indolent Non-Hodgkin Lymphoma Patients: A Real-world Taiwan Observation Multicenter Study
Primary Objective
To describe the real-world utilization of copanlisib for the treatment of relapse/refractory iNHL in Taiwan
Number of Sites
4
Period of Study
From:2022 Q2 to:2024 Q4
Number of Patients
50人
IRB Approval Date
NTUH 2022/04/25
KFSYSCC 2022/05/28
CYCH In Progress
KHCGMH In preparation
Publication Plan / Date
Unknown